Janlyn Anthony, PA
Medical · Richmond, VANPI 1295757805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 950 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 950 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- Johnson & Johnson$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $7K from 17 others
What the payments were for
- Food & beverage$17,15998%
- Education$4132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 136 | $2,757 |
| AbbVie | 154 | $2,276 |
| Neurocrine Biosciences, Inc. | 81 | $1,471 |
| Sunovion Pharmaceuticals Inc. | 95 | $1,424 |
| Johnson & Johnson | 67 | $1,378 |
| Vanda Pharmaceuticals Inc. | 54 | $1,309 |
| Alkermes, Inc. | 55 | $1,274 |
| Teva Pharmaceuticals USA, Inc. | 59 | $883 |
| Otsuka America Pharmaceutical, Inc. | 34 | $697 |
| Lundbeck LLC | 41 | $693 |
| Bausch Health US, LLC | 34 | $660 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $659 |
| E.r. Squibb & Sons, L.L.C. | 16 | $511 |
| Tris Pharma Inc | 31 | $429 |
| Corium, LLC | 13 | $366 |
| Axsome Therapeutics, Inc. | 12 | $334 |
| Supernus Pharmaceuticals, Inc. | 7 | $104 |
| Neos Therapeutics, LP | 6 | $102 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Merck | 4 | $63 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| TMS Neurohealth Centers Inc. | 3 | $39 |
| Indivior Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$932
- CAPLYTA$607
- INGREZZA$497
- Fanapt$245
- VRAYLAR$241
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- INVEGA$125
- SPRAVATO$125
- Dyanavel XR$125
- Quillivant$125
- Quillichew ER$125
- Austedo XR$122
- ARISTADA INITIO$122
- COBENFY$121
- Auvelity$121
- REXULTI$120
- LYBALVI$111
How this compares
$17,572 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $258,823 |
| Austedo XrDeutetrabenazine | 20 | $178,913 |
| RexultiBrexpiprazole | 31 | $101,143 |
| VraylarCariprazine Hcl | 55 | $89,628 |
| Abilify MaintenaAripiprazole | 27 | $69,909 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $51,389 |
| TrintellixVortioxetine Hydrobromide | 45 | $50,391 |
| Invega SustennaPaliperidone Palmitate | 12 | $41,831 |
| UzedyRisperidone | 13 | $40,974 |
| BelsomraSuvorexant | 54 | $26,411 |
| Paliperidone ErPaliperidone | 34 | $8,494 |
| Aripiprazole | 118 | $6,601 |
| Lurasidone Hcl | 65 | $5,773 |
| Clozapine | 78 | $4,908 |
| Quetiapine Fumarate | 130 | $3,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,471 | $258,82333 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $883 | $219,88733 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $697 | $171,05258 claims |
| AbbVieVraylar | $2,276 | $89,62855 claims |
| Alkermes, Inc.Lybalvi | $1,274 | $51,38933 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $659 | $50,39145 claims |
| Johnson & JohnsonInvega Sustenna | $1,378 | $41,83112 claims |
| MerckBelsomra | $63 | $26,41154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Richmond
- Sara VillalonaRichmond$240K
- Nicholas DeptulaRichmond$17K
- Lori WoodRichmond$13K
- Emily RevensonRichmond$12K
- Thomas CawleyRichmond$8K
- Aesha ParikhRichmond$8K
- Jenny AmbrosinoRichmond$7K
- Michele RhoeRichmond$6K
- Elizabeth RhamyRichmond$6K
- Bryan UrquhartFredericksburg$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.